1
|
Manser M, Jeyanathan V, Jeyanathan M, Feng X, Dolovich MB, Xing Z, Cranston ED, Thompson MR. Design Considerations for Intratracheal Delivery Devices to Achieve Proof-of-Concept Dry Powder Biopharmaceutical Delivery in Mice. Pharm Res 2023; 40:1165-1176. [PMID: 36991226 PMCID: PMC10057681 DOI: 10.1007/s11095-023-03492-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Accepted: 02/26/2023] [Indexed: 03/31/2023]
Abstract
PURPOSE Intratracheal delivery and consistent dosing of dry powder vaccines is especially challenging in mice. To address this issue, device design of positive pressure dosators and actuation parameters were assessed for their impacts on powder flowability and in vivo dry powder delivery. METHODS A chamber-loading dosator assembled with stainless-steel, polypropylene or polytetrafluoroethylene needle-tips was used to determine optimal actuation parameters. Powder loading methods including tamp-loading, chamber-loading and pipette tip-loading were compared to assess performance of the dosator delivery device in mice. RESULTS Available dose was highest (45%) with a stainless-steel tip loaded with an optimal mass and syringe air volume, primarily due to the ability of this configuration to dissipate static charge. However, this tip encouraged more agglomeration along its flow path in the presence of humidity and was too rigid for intubation of mice compared to a more flexible polypropylene tip. Using optimized actuation parameters, the polypropylene pipette tip-loading dosator achieved an acceptable in vivo emitted dose of 50% in mice. After administering two doses of a spray dried adenovirus encapsulated in mannitol-dextran, high bioactivity was observed in excised mouse lung tissue three days post-infection. CONCLUSIONS This proof-of-concept study demonstrates for the first time that intratracheal delivery of a thermally stable, viral-vectored dry powder can achieve equivalent bioactivity to the same powder, reconstituted and delivered intratracheally. This work may guide the design and device selection process for murine intratracheal delivery of dry powder vaccines to help progress this promising area of inhalable therapeutics.
Collapse
Affiliation(s)
- Myla Manser
- Department of Chemical Engineering, McMaster University, Hamilton, ON, L8S 4L7, Canada
| | - Vidthiya Jeyanathan
- McMaster Immunology Research Centre and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, L8S 4L7, Canada
| | - Mangalakumari Jeyanathan
- McMaster Immunology Research Centre and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, L8S 4L7, Canada
| | - Xueya Feng
- McMaster Immunology Research Centre and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, L8S 4L7, Canada
| | - Myrna B Dolovich
- Firestone Research Aerosol Laboratory, Research Institute of St Joseph's Hospital, St. Joseph's Healthcare and Faculty of Health Sciences, Department of Medicine, McMaster University, Hamilton, ON, L8N 4A6, Canada
| | - Zhou Xing
- McMaster Immunology Research Centre and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, L8S 4L7, Canada
| | - Emily D Cranston
- Department of Chemical Engineering, McMaster University, Hamilton, ON, L8S 4L7, Canada
- Department of Wood Science, University of British Columbia, 2424 Main Mall, Vancouver, BC, V6T 1Z4, Canada
- Department of Chemical and Biological Engineering, University of British Columbia, 2360 East Mall, Vancouver, BC, V6T 1Z3, Canada
| | - Michael R Thompson
- Department of Chemical Engineering, McMaster University, Hamilton, ON, L8S 4L7, Canada.
| |
Collapse
|
2
|
Singh V, Son YJ, Dolovich M, Xing Z, Cranston ED, Thompson MR. Screening amino acid additives as aerosolization modifiers for spray dried inhalable viral-vectored vaccines. J Drug Deliv Sci Technol 2022. [DOI: 10.1016/j.jddst.2022.103815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
3
|
Manser M, Morgan BA, Feng X, Rhem RG, Dolovich MB, Xing Z, Cranston ED, Thompson MR. Dextran Mass Ratio Controls Particle Drying Dynamics in a Thermally Stable Dry Powder Vaccine for Pulmonary Delivery. Pharm Res 2022; 39:2315-2328. [PMID: 35854077 PMCID: PMC9296218 DOI: 10.1007/s11095-022-03341-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Accepted: 07/11/2022] [Indexed: 11/24/2022]
Abstract
PURPOSE Thermally stable, spray dried vaccines targeting respiratory diseases are promising candidates for pulmonary delivery, requiring careful excipient formulation to effectively encapsulate and protect labile biologics. This study investigates the impact of dextran mass ratio and molecular weight on activity retention, thermal stability and aerosol behaviour of a labile adenoviral vector (AdHu5) encapsulated within a spray dried mannitol-dextran blend. METHODS Comparing formulations using 40 kDa or 500 kDa dextran at mass ratios of 1:3 and 3:1 mannitol to dextran, in vitro quantification of activity losses and powder flowability was used to assess suitability for inhalation. RESULTS Incorporating mannitol in a 1:3 ratio with 500 kDa dextran reduced viral titre processing losses below 0.5 log and displayed strong thermal stability under accelerated aging conditions. Moisture absorption and agglomeration was higher in dextran-rich formulations, but under low humidity the 1:3 ratio with 500 kDa dextran powder had the lowest mass median aerodynamic diameter (4.4 µm) and 84% emitted dose from an intratracheal dosator, indicating strong aerosol performance. CONCLUSIONS Overall, dextran-rich formulations increased viscosity during drying which slowed self-diffusion and favorably hindered viral partitioning at the particle surface. Reducing mannitol content also minimized AdHu5 exclusion from crystalline regions that can force the vector to air-solid interfaces where deactivation occurs. Although increased dextran molecular weight improved activity retention at the 1:3 ratio, it was less influential than the ratio parameter. Improving encapsulation ultimately allows inhalable vaccines to be prepared at higher potency, requiring less powder mass per inhaled dose and higher delivery efficiency.
Collapse
Affiliation(s)
- Myla Manser
- Department of Chemical Engineering, McMaster University, Hamilton, ON, L8S 4L7, Canada
| | - Blair A Morgan
- Department of Chemical Engineering, McMaster University, Hamilton, ON, L8S 4L7, Canada
| | - Xueya Feng
- McMaster Immunology Research Centre and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, L8S 4L7, Canada
| | - Rod G Rhem
- Firestone Research Aerosol Laboratory, St. Joseph's Healthcare and Department of Medicine, McMaster University and Hamilton, Hamilton, ON, L8N 4A6, Canada
| | - Myrna B Dolovich
- Firestone Research Aerosol Laboratory, St. Joseph's Healthcare and Department of Medicine, McMaster University and Hamilton, Hamilton, ON, L8N 4A6, Canada
| | - Zhou Xing
- McMaster Immunology Research Centre and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, L8S 4L7, Canada
| | - Emily D Cranston
- Department of Chemical Engineering, McMaster University, Hamilton, ON, L8S 4L7, Canada.,Department of Wood Science, University of British Columbia, 2424 Main Mall, Vancouver, BC, V6T 1Z4, Canada.,Department of Chemical and Biological Engineering, University of British Columbia, 2360 East Mall, Vancouver, BC, V6T 1Z3, Canada
| | - Michael R Thompson
- Department of Chemical Engineering, McMaster University, Hamilton, ON, L8S 4L7, Canada.
| |
Collapse
|